|4Feb 25, 8:08 PM ET

Drake Lorin 4

4 · Sagent Pharmaceuticals, Inc. · Filed Feb 25, 2013

Insider Transaction Report

Form 4
Period: 2013-02-21
Drake Lorin
VP, Sales and Marketing
Transactions
  • Award

    Stock Option to Buy

    2013-02-21+8,4998,499 total
    Exercise: $16.45Exp: 2023-02-21Common Stock (8,499 underlying)
  • Award

    Common Stock

    2013-02-21+4,92422,478 total
Footnotes (1)
  • [F1]The option vests in four equal annual installments beginning on February 21, 2014.

Documents

1 file
  • 4
    rrd371544.xmlPrimary